| Patent Number |
Title Of Patent |
Date Issued |
| RE39094 |
Pyropheophorbides and their use in photodynamic therapy |
May 9, 2006 |
| Pyropheophorbide compounds are injected into a host and accumulate in tumor tissue to a higher degree than surrounding normal tissues. When the pyropheophorbide compounds are exposed to a particular wavelength of light the compounds become cytotoxic and destroy the tumor or diseased |
| RE38994 |
Pyropheophorbides conjugates and their use in photodynamic therapy |
February 28, 2006 |
| Conjugate are formed by covalently linking a target-specific compound to pyropheophorbide compound which conjugated are injected into a host and accumulate in tumor tissue to a higher degree than surrounding normal tissues. When the pyropheophorbide compound component of the conjugate is |
| 7592421 |
HLA class II peptide mimics |
September 22, 2009 |
| The present invention provides peptide mimics for HLA class II antigens. The peptide mimics were identified by panning phage display peptide libraries with anti-HLA class II monoclonal antibodies. The peptide mimics inhibit the binding of an anti-HLA class II antigen antibody to HLA |
| 7585945 |
Use of recombinant heat shock protein complexed to kidney cancer antigen |
September 8, 2009 |
| A heat shock protein in combination with carbonic anhydrase IX and a method for improving immune response to carbonic anhydrase IX in a mammal by complexing it with a heat shock protein prior to administration to the mammal. |
| 7585522 |
Oral immunology using plant product containing a non-enteric pathogen antigen |
September 8, 2009 |
| A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunorec |
| 7572466 |
Oral immunology using plant product containing a non-enteric pathogen antigen |
August 11, 2009 |
| A method for obtaining an immune response to a non-enteric pathogen antigen (NEPA) such as hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the NEPA. It has now been discovered that the animal may be made immunorec |
| 7569221 |
Compositions and methods for identifying agents that alter expression of survivin |
August 4, 2009 |
| Provided are compositions and methods for identifying agents that can modulate expression of the human survivin gene. The compositions include eukaryotic cells that contain a human survivin promoter sequence operably linked to a reporter gene. The method comprises determining whether a |
| 7534818 |
Method of reducing alopecia and bladder toxicity of cyclophosphamide |
May 19, 2009 |
| The present invention discloses a method for reducing alopecia and bladder toxicity associated with the anti-cancer agent cyclophosphamide. The method comprises administering to an individual, in need of such a treatment, cyclophosphamide and a selenium compound. The selenium compoun |
| 7527810 |
Oral immunology using plant product containing hepatitis surface antigen |
May 5, 2009 |
| A method for obtaining an immune response to hepatitis B surface antigen (HBsAg) by feeding the antigen in a plant material to an animal that is immunoreceptive to the HBsAg. It has now been discovered that the animal may be made immunoreceptive to HBsAg either by administering the plant |
| 7501509 |
Water soluble tetrapyrollic photosensitizers for photodynamic therapy |
March 10, 2009 |
| A tetrapyrollic photosensitizer compound having at least one pendant --CH.sub.2CH.sub.2CON(CH.sub.2CON(CH.sub.2COOH).sub.2).sub.2 or --N(CH.sub.2COOH).sub.2 group or esters thereof said tetrapyrollic compound being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimid |
| 7479370 |
Detection of 13q14 chromosomal alterations |
January 20, 2009 |
| The present invention relates to methods for detection of chromosomal alterations which are associated with the presence of various leukemias and lymphomas. The method comprises the steps of obtaining a biological sample comprising lymphocytes from an individual and assaying the sample |
| 7449303 |
Use of JAG2 expression in diagnosis of plasma cell disorders |
November 11, 2008 |
| The present invention is based on the finding that plasma cell disorders such as Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance are characterized by an increase in the expression of JAG2. Accordingly, the present invention provides a method for diagnosis of plasma |
| 7427608 |
Protection against and treatment of hearing loss |
September 23, 2008 |
| The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss. |
| 7425414 |
Method of prognosis of metastasis by detection of FRA12E fragile site within the SMRT gene/locus |
September 16, 2008 |
| Provided are methods for prognostic prediction of metastasis. The method comprises identifying the presence or absence of a fragile site FRA12E on chromosome 12q24 at the SMRT gene locus. The presence of FRA12E in an individual can be determined in cell samples obtained from the individu |
| 7384785 |
Diagnostic test for West Nile virus |
June 10, 2008 |
| The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen |
| 7355033 |
Screening for West Nile Virus antiviral therapy |
April 8, 2008 |
| The instant invention provides stable and novel lineage I WNV reverse genetics systems, and methods for making the reverse genetics systems, specifically, a fully-infectious lineage I WNV cDNA or replicon system engineered with one or more nucleotide sequences each encoding a reporter |
| 7351547 |
Diagnostic test for West Nile virus |
April 1, 2008 |
| The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen |
| 7351530 |
Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-sm |
April 1, 2008 |
| The present invention provides a method for detection of loss of heterozygosity (LOH) at human chromosome segment 11p15.5 in a tumor sample from a patient with non-small-cell lung cancer (NSCLC), and a method for prognosis of the patient's disease progression. The prognosis is useful |
| 7348153 |
Method for identifying and designing immunogenic peptides |
March 25, 2008 |
| The invention provides a method for identifying peptides for use in increasing a cytotoxic T lymphocytes (CTL) response to an antigen. The method comprises the steps of comparing the amino acid sequence of the VH and/or VL portions of an anti-idiotypic monoclonal antibody to the amino |
| 7344830 |
Heteroduplex tracking assay |
March 18, 2008 |
| A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the pre |
| 7323313 |
Methods for protein interaction determination |
January 29, 2008 |
| The present invention provides a method for identifying a plurality of pairs of interacting proteins and plasmids for use in the method. The pair of plasmids is adapted for use in a modified two hybrid system wherein wherein each plasmid comprises a recombinase recognition site. The |
| 7306801 |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
December 11, 2007 |
| Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered |
| 7294458 |
Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients |
November 13, 2007 |
| A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the pre |
| 7282203 |
Use of NOTCH pathway interfering agents for treatment of plasma cell disorders |
October 16, 2007 |
| The present invention provides a method for reducing the severity of, or treatment of, plasma cell disorders. The method comprises the step of administering to an individual afflicted with a plasma cell disorder, a composition comprising an antibody directed to the extracellular portion |
| 7238523 |
p53as protein and antibody therefor |
July 3, 2007 |
| The invention comprises plasmids and viral vectors containing an animal p53as cDNA sequence. A portion of the p53as sequence may be identified to a position of wild type p53 gene from the same animal. In preferred embodiments, the p53as is mouse or human p53as. A preferred viral vector |
| 7166719 |
Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy |
January 23, 2007 |
| Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using photodynamic methods. In particular, photosensitizer compounds that collect in hyperproliferative tissue are provi |
| 7147840 |
Oxo-bacteriopyropheophorbide-a carboxylic acid and esters thereof |
December 12, 2006 |
| A compound having the structural formula: ##STR00001## where R is H or lower alkyl of 1 through 12 carbon atoms. In general, the compounds of the invention are 13.sup.2-Oxo-bacteriopyropheophorbide--a carboxylic acid and C.sub.1 C.sub.12 alkyl esters thereof. A method for the prepar |
| 7129225 |
Protection against and treatment of hearing loss |
October 31, 2006 |
| The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss. |
| 7098195 |
Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells |
August 29, 2006 |
| The present invention provides compositions and methods for inhibiting cell migration, e.g., lymphocytes and inflammation. The invention also provides an improved process for preparing fluorinated N-acetylglucosamines. |
| 7097836 |
Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody |
August 29, 2006 |
| The present invention provides a method for enhancing the efficacy of chemotherapeutic agents for therapy of cancer and other angiogenesis-associated diseases such as rheumatoid arthritis. The method comprises the steps of administering to an individual in need of treatment, a combin |
| 7097826 |
Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N.sub.2S.sub.2 conjugates fo |
August 29, 2006 |
| A compound comprising a chemical combination of a photodynamic tetra-pyrrolic compound with a plurality of radionuclide element atoms such that the compound may be used to enhance MR imaging and also be used as a photodynamic compound for use in photodynamic therapy to treat hyperpro |
| 7078014 |
Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N.sub.2S.sub.2 conjugate |
July 18, 2006 |
| A method for MR imaging that comprises conducting the MR imaging after injecting compositions that are chemical combination of porphyrins, chlorins, bacteriochlorins, and related tetra-pyrrolic compounds with radioactive elements such as Technetium.sup.99, Gadolinium, Indium.sup.111 |
| 7053210 |
Efficient synthesis of pyropheophorbide a and its derivatives |
May 30, 2006 |
| A process for the preparation of pyropheophorbide a and its derivatives, including 3-devinyl-3-(1'-hexyloxy)ethyl-pyropheophorbide-a, otherwise known as HPPH, is provided. The process involves treating chlorin e.sub.6, in the form of its trimethyl ester, with a base, followed by heat |
| 6998237 |
GD3 peptide mimics |
February 14, 2006 |
| The present invention provides peptide mimics for GD3 ganglioside. The peptide mimics were identified by panning phage display peptide libraries with an anti-GD3 monoclonal antibody. The peptide mimics inhibit the binding of an anti-GD3 antibody to GD3 positive cells and also elicit |
| 6991805 |
Temperature sensitive control of liposome-cell adhesion |
January 31, 2006 |
| The present invention provides a liposomal composition for targeted delivery of drugs. The composition comprises poloxamer molecules and liposomes encapsulating one or more delivery agents. At above the critical micellar temperature of the poloxamer, a fraction of the poloxamer molec |
| 6984384 |
Stress protein compositions and methods for prevention and treatment of cancer and infectious di |
January 10, 2006 |
| Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide |
| 6977271 |
Method for inhibition of angiogenesis and vasculogenesis |
December 20, 2005 |
| The present invention provides a method for inhibiting or preventing angiogenesis in animals and humans comprising the steps of administering to the animal or human an effective amount of one or more isomers of conjugated linoleic acid ("CLA"). The CLA may be administered in the form |
| 6965009 |
p53 as protein and antibody therefor |
November 15, 2005 |
| In accordance with the present invention, we have discovered and purified a protein designated herein as p53as, which protein is present in normal cells of a mammal and is essentially identical to known normal growth controlling protein p53 of the same mammal, at least until the final 50 |
| 6964778 |
Temperature controlled content release from liposomes |
November 15, 2005 |
| The present invention provides a liposomal composition for targeted delivery of drugs. The composition comprises large unilamellar vesicles (LUV) encapsulating poloxamers and one or more delivery agents. The composition and concentration of the poloxamer inside the LUVs is such that |
| 6939948 |
GD2 peptide mimics |
September 6, 2005 |
| The present invention provides peptide mimics for GD2 ganglioside. The peptide mimics were identified by panning phage display peptide libraries with an anti-GD2 monoclonal antibody. The identified peptide mimics can be used as immunogens for cancer therapy such as for melanoma and n |
| 6939893 |
Method of reducing toxicity of anticancer agents |
September 6, 2005 |
| The present invention discloses a method for enhancing the efficacy of anti-cancer agents. The method comprises administering to an individual, in need of such a treatment, an anti-cancer agent and a selenium compound. The selenium compounds may be administered before, during or after |
| 6868221 |
Fiber optic positioner |
March 15, 2005 |
| The present invention relates to an apparatus which includes a polypod support which includes a fiber optic supporting platform. The fiber optic supporting platform includes an opening. The apparatus further includes at least three legs forming a tripod, each of the legs having two ends, |
| 6849607 |
Galectin recognized photosensitizers for photodynamic therapy |
February 1, 2005 |
| Purpurin-carbohydrate conjugates and their method of preparation and use for treatment of cancer cells. The conjugates have the general formula: ##STR1##wherein R.sub.6 and R.sub.7 taken together are .dbd.NR.sub.11 or are independently --OR.sub.11, where at least one R.sub.11 is preferab |
| 6782167 |
Light beam splitter |
August 24, 2004 |
| An apparatus that efficiently and accurately directs or splits a non-polarized light beam input from a fiber optic into one, two, four or eight output beams wherein the light beam input is passed through a collimator, the apparatus uses non-polarizing beam splitters and the output be |
| 6752769 |
Core bite biopsy needle |
June 22, 2004 |
| A biopsy needle that is based upon an opening at the tip of the needle, not the side, that permits the entire sample to be cut from the patient yet has smooth sides to reduce injury to the patient when the needle is inserted. The needle of the invention has a coaxial inner needle or tube |
| 6727060 |
Analysis of HIV-1 coreceptor use in the clinical care of HIV-1-infected patients |
April 27, 2004 |
| A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the pre |
| 6692643 |
Method for detecting PSA and its molecular forms using thiophilic gel on magnetic beads |
February 17, 2004 |
| A method for capturing PSA and its molecular forms that may be in a fluid biological material including the steps of: preparing a bed of magnetic beads by binding thiophilic ligands to the beds where the thiophilic ligands bind PSA and its complexes, said thiophilic ligands comprising a |
| 6624187 |
Long wave length absorbing bacteriochlorin alkyl ether analogs |
September 23, 2003 |
| Novel compounds that either preferentially absorb into hyperproliferative tissue and absorb light efficiently at a wavelength of between about 700 and about 850 nm or act as intermediates for such absorbing compounds. More particularly, the compounds of the invention have the formula: |
| 6620779 |
Method of enhancing the efficacy of anti-tumor agents |
September 16, 2003 |
| A method for enhancing the effect of anti-tumor agents on solid tumors is provided. The method comprises administering to an individual an anti-tumor agent and a hematocrit elevator. The hematocrit elevator may be administered before or concurrently with the anti-tumor agent. |
| 6605465 |
Methods for avoiding maternal immunity |
August 12, 2003 |
| What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from herpesvirus. In one embodiment, the foreign DNA is expressed in a host by the production of a herpesvirus glycoprotein. In another embodiment, the forei |
